<DOC>
	<DOCNO>NCT00703586</DOCNO>
	<brief_summary>Hypothesis : Intensification current ARV regimens maraviroc result complete suppression viral replication , particularly gastrointestinal mucosa resultant reduction marker immune activation improve GI immune reconstitution .</brief_summary>
	<brief_title>Study Antiviral Immunological Effects Intensification Suppressive Antiretroviral Therapy With Maraviroc</brief_title>
	<detailed_description>- DURATION : Subjects participate minimum 28 week . - SAMPLE SIZE : 18 subject randomize 2:1 continued ARVs plus maraviroc versus continue ARVs plus additional ARV determine base baseline ARV regimen . - REGIMEN : At entry , subject randomize one follow 2:1 ratio : ARM A : Intensification maraviroc 24 week one follow dos : - 150 mg orally BID coadministered ritonavir-boosted protease inhibitor - 600 mg orally BID coadministered efavirenz nevirapine ARM B Intensification additional NRTI 12 week cross maraviroc intensification additional 12 week : - Addition abacavir 600 mg orally daily tenofovir contain regimen 12 week replace abacavir maraviroc - Addition alternate FDA approve NRTI [ zidovudine ( AZT ) didanosine ( ddi ) ] standard oral dose tenofovir contain regimen 12 week ( participant decline abacavir therapy ) replace alternate NRTI maraviroc . The objective study : To determine whether intensification current ARV regimens maraviroc result complete suppression viral replication improve immune reconstitution GI mucosal lymphoid compartment base : - Reduction normalized level CD4+MMC HIV-1 RNA determine PCR pre- post- intensification week 12 Arm A versus Arm B . - Reduction normalized level CD4+ mucosal mononuclear cell ( MMC ) HIV-1 RNA week 12 compare baseline Arm A . - Reduction % CD4+MMC HIV-1 RNA positive determine PCR pre- post- intensification Arm A Arm B well week 12 24 post maraviroc intensification . - Levels CD4+ T cell GALT ( % flow absolute # immunohistochemistry ) . - Phenotype cell GALT flow ( memory , naive , R5 , X4 , dual expressing ) . - Levels activation CD4 CD8 PB GALT use HLA DR CD 38 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Documented treatment combination antiviral therapy ( ARV ) acute early HIV1 infection define : Negative ELISA/Western Blot indeterminate Western Blot presence HIV1 RNA &gt; 5,000 copies/ml Positive HIV1 serology detuned ELISA O.D . value 1.0 A documented negative serology within 180 day screen positive HIV1 serology screen Treatment least one year ARVs Plasma HIV1 RNA level detection least 6 month CCR5 tropic virus pretreatment use Monogram assay GI biopsy study entry Agree subsequent GI biopsy 12 24 week Laboratory value obtain within 45 day prior study entry . Absolute neutrophil count ( ANC ) ≥500/mm³ Hemoglobin ≥9.0 g/dL Platelet count ≥80,000/mm³ AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase &lt; 5.0 x ULN Total bilirubin ≤ 2.5 X ULN atazanavir contain regimen PT/PTT within 1.5 control Calculated creatinine clearance ≥60 mL/min estimate Cockcroft Gault equation : For men , ( 140 age year ) x ( body weight kg ) / ( serum creatinine mg/dL x 72 ) = CrCl ( mL/min ) For woman , multiply result 0.85 = CrCl ( mL/min ) NOTE : A program assist calculation available DMC web site : http : //www.fstrf.org/ACTG/ccc.html For woman reproductive potential , negative serum urine pregnancy test within 48 hour prior initiate study medication unless otherwise specify product labeling . Female candidate reproductive potential defined girl reach menarche woman postmenopausal least 24 consecutive month ( i.e. , menses within precede 24 month ) undergo surgical sterilization ( e.g. , hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) . Contraception requirement : Female candidate reproductive potential , participate sexual activity could lead pregnancy , must agree use least one reliable method contraception receive protocolspecified drug 6 week stop medication . Male Candidates : If heterosexual male , sexual partner must agree use acceptable method birth control entire study . Acceptable method birth control include intrauterine device ( IUD ) , diaphragm spermicide , condom sex . Oral contraceptive alone acceptable method birth control . Men woman age ≥18 year . Participants must HLAB5701 negative take abacavir part regimen . Ability willingness subject give write informed consent . Currently breastfeed . Use immunomodulators ( e.g. , interleukin , interferon , cyclosporine ) , HIV vaccine , systemic cytotoxic chemotherapy , investigational therapy within 30 day prior study entry . NOTE : Subjects receive stable physiologic glucocorticoid dos , define prednisone ≤ 10 mg/day , exclude . Known allergy/sensitivity study drug formulation . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Serious illness require systemic treatment and/or hospitalization candidate either completes therapy clinically stable therapy , opinion site investigator , least 7 day prior study entry . Pretreatment viral population either dual mixed tropic X4 tropic use Monogram assay Current imprisonment involuntary incarceration medical facility psychiatric physical ( e.g. , infectious disease ) illness . Any clinical condition prior therapy , opinion investigator , would make subject unsuitable study unable comply requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Maraviroc</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>